From The Editor

  1. FDA's Psychedelic Reckoning 11/27/2024

    Cybin CEO Doug Drysdale discusses learnings from psychedelic drug clinical trial missteps, provides examples of the benefits of FDA breakthrough therapy designation, and talks about why RFK Jr. as HHS Secretary could be a win for psychedelic drug developers.

  2. CEO Panel Talks IRA Impact At Galien Forum 11/14/2024

    A panel of biopharmaceutical leaders convened at the Galien Forum discussed the impacts of the Inflation Reduction Act so far, and what's likely to come in the year ahead.

  3. A Bioethicist Weighs In On Obesity Drugs 10/31/2024

    Anne Zimmerman, editor-in-chief of the Columbia University online journal, Voices in Bioethics discusses her concerns over the use of GLP-1 weight loss drugs in the U.S.

  4. New Leadership At The Cancer Research Institute 9/27/2024

    Alicia Zhou, Ph.D., the incoming CEO at the Cancer Research Institute, talks about her plans and approach to moving a 70-year old cancer research nonprofit into the future.

  5. A Systems Approach To Parkinson's Disease 8/30/2024

    New research into Parkinson's disease is strengthening the connection between an unhealthy gut and brain disorders.

  6. GLP-1 Drugs Driving Big Budget Impact: PwC's Medical Cost Trend 2025 8/1/2024

    PwC's Medical Cost Trend: Behind The Numbers 2025 report offers details on the key 'inflators' and 'deflators' impacting medical spending next year. The key inflator? You guessed it, weight loss drugs.

  7. Reading The Room In Oncology Drug Development 7/11/2024

    Oral conversations with the FDA about trial design and protocol can lead to questions, and answers, that help drug developers avoid costly surprises and misunderstandings.

  8. Ten Years In, Project Data Sphere Is Snowballing 6/21/2024

    Project Data Sphere, an open access data sharing initiative, is expanding into closed access preclinical research and developing AI models that can benefit drug developers.

  9. Drug Discovery And Development, Powered By Physician Intelligence 5/15/2024

    For Nuvalent CEO James Porter, physician intelligence is more important than artificial intelligence in discovering and developing new therapies that tackle key unmet needs among cancer patients.

  10. Why Fusion Pharma Is The Latest Billion Dollar Big Pharma Buy In Radiopharmaceuticals 3/22/2024

    AstraZeneca's $2.4 billion acquisition of Fusion Pharma is the third billion dollar radiopharmaceuticals deal in recent months. John Valliant, Fusion's founder and CEO, explains why alpha-emitters are better than beta-emitters, and why radiopharmaceuticals are poised for substantial growth.